Nuala Brennan
Technik-/Wissenschafts-/F&E-Leiter bei MOONLAKE IMMUNOTHERAPEUTICS
Profil
Ms. Nuala Brennan is a Chief Clinical Development Officer at MoonLake Immunotherapeutics and a Chief Clinical Development Officer at Moonlake Immunotherapeutics Ltd.
Ms. Brennan was previously employed as a Vice President-Clinical Operations by Kymab Ltd.
She received her undergraduate degree from the University of Leicester.
Aktive Positionen von Nuala Brennan
| Unternehmen | Position | Beginn |
|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2021 |
| Moonlake Immunotherapeutics Ltd. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2021 |
Ehemalige bekannte Positionen von Nuala Brennan
| Unternehmen | Position | Ende |
|---|---|---|
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2021 |
Ausbildung von Nuala Brennan
| University of Leicester | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Moonlake Immunotherapeutics Ltd. | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
